|
Brussels, |
|
Open preview
|
eDossier EUMED
EU ACTIONS ON MEDICAL DEVICES, IVD & BIOMEDICAL TECHNOLOGIESeDossier DaaS* · Cloud-based annual access
Updated: July 2026
by eEuropa.org @ 2021-2026 Content & Features
|
Already an eEuropa member (free or paid)?
Before purchasing an additional eEuropa product, please log in to your eEuropa account first, then return to this page to complete your purchase. |
Summary
This eDossier provides a structured and updated analysis of European Union action on medical devices, in vitro diagnostic medical devices and biomedical technologies. It covers the MDR and IVDR, the 2025–2026 simplification agenda, EUDAMED, notified-bodies, clinical and performance evidence, market surveillance, critical device availability and the evolving role of EU agencies and governance bodies.
The eDossier examines the biomedical dimension of EU medical technology policy, including diagnostics, laboratory technologies, implantable and connected devices, AI-enabled medical devices, software as medical device, orphan and breakthrough devices, health data, cybersecurity and the European Health Data Space.
It places EU medical-device regulation within a broader strategic context: industrial competitiveness, SME burden, patient access, innovation capacity, EU research and funding instruments, health-system resilience and Europe’s ambition to strengthen its biomedical and health-technology ecosystem.
A specific focus is dedicated to the interaction between regulation and innovation. The eDossier explains how MDR/IVDR compliance increasingly intersects with AI governance, data governance, clinical evidence, HTA, cybersecurity, market surveillance and EU funding opportunities.
The eDossier is designed for manufacturers, biomedical companies, diagnostics developers, consultants, hospitals, public authorities, investors, researchers and policy professionals who need a clear and operational overview of EU medical devices policy, regulation, funding and market dynamics.
The eDossier examines the biomedical dimension of EU medical technology policy, including diagnostics, laboratory technologies, implantable and connected devices, AI-enabled medical devices, software as medical device, orphan and breakthrough devices, health data, cybersecurity and the European Health Data Space.
It places EU medical-device regulation within a broader strategic context: industrial competitiveness, SME burden, patient access, innovation capacity, EU research and funding instruments, health-system resilience and Europe’s ambition to strengthen its biomedical and health-technology ecosystem.
A specific focus is dedicated to the interaction between regulation and innovation. The eDossier explains how MDR/IVDR compliance increasingly intersects with AI governance, data governance, clinical evidence, HTA, cybersecurity, market surveillance and EU funding opportunities.
The eDossier is designed for manufacturers, biomedical companies, diagnostics developers, consultants, hospitals, public authorities, investors, researchers and policy professionals who need a clear and operational overview of EU medical devices policy, regulation, funding and market dynamics.
* DaaS, Cloud-Based
This publication is offered as an eDossier DaaS, combining an updated digital document with 12-month cloud-based access. Subscribers can access both the web version and the PDF version online from computers, tablets or smartphones.
The document is not sold as a static file. It remains an updated eEuropa intelligence resource during the subscription period. Updates may include regulatory changes, new EU guidance, market developments and additional source links.
Access is provided for one year from subscription. Ownership of the document is not transferred; subscribers receive access rights to the updated eDossier according to the applicable licence terms.
Sources
Sources: European Union, European Commission, EUR-Lex, European Medicines Agency, MDCG, EUDAMED, European Parliament, EESC, HaDEA, Horizon Europe, EU4Health, Innovative Health Initiative, MedTech Europe and eEuropa Health Hub, 2017–2026.
This publication is offered as an eDossier DaaS, combining an updated digital document with 12-month cloud-based access. Subscribers can access both the web version and the PDF version online from computers, tablets or smartphones.
The document is not sold as a static file. It remains an updated eEuropa intelligence resource during the subscription period. Updates may include regulatory changes, new EU guidance, market developments and additional source links.
Access is provided for one year from subscription. Ownership of the document is not transferred; subscribers receive access rights to the updated eDossier according to the applicable licence terms.
Sources
Sources: European Union, European Commission, EUR-Lex, European Medicines Agency, MDCG, EUDAMED, European Parliament, EESC, HaDEA, Horizon Europe, EU4Health, Innovative Health Initiative, MedTech Europe and eEuropa Health Hub, 2017–2026.
